Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome

• Status: Completed
• Trial end date: 2005-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether ecabet ophthalmic solution is an effective treatment for dry eye syndrome

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bausch & Lomb Incorporated
• Treatments: Ecabet; Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Agree to avoid systemic & topical ophthalmic meds & disallowed meds

• Have a best corrected visual acuity (BCVA) of 20/40 with pinhole or better in each eye

• Diagnosis of moderate dry eye syndrome

Exclusion Criteria:

• Uncontrolled ocular or systemic disease that could interfere with study

• Diagnosis of Sjogren's syndrome, lacrimal obstruction, reflex, lid-related or contact lens-related dry eye syndrome(DES); significant anterior blepharitis or meibomianitis

• Contraindications or hypersensitivity to use of study meds or components

• Wear contact lenses

• Secondary dry eye to surgery

• Eye surgery (including laser) within 6 months

• Use of systemic or topical ophthalmic meds within 14 days

• Punctal plugs in one or both eyes in place for <45 days

• Permanent occlusion of the lacrimal puncta